Akebia Therapeutics Inc. (NASDAQ:AKBA) shares, rose in value, with the stock price down by -2.92% to the previous day’s close as strong demand from buyers drove the stock to $1.33.
Actively observing the price movement in the last trading, the stock closed the session at $1.37. Referring to stock’s 52-week performance, its high was $2.48, and the low was $0.65. On the whole, AKBA has fluctuated by -33.50% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 189.09M, with a low estimate of 40.1M and a high estimate of 56M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 46.34M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AKBA’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of AKBA currently trading nearly -12.56% and -15.85% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 36.87, while the 7-day volatility ratio is showing 4.20% which for the 30-day chart, stands at 9.29%. Furthermore, Akebia Therapeutics Inc. (AKBA)’s beta value is 0.91, and its average true range (ATR) is 0.12.
A comparison of Akebia Therapeutics Inc. (AKBA) with its peers suggests the former has fared considerably weaker in the market. AKBA showed an intraday change of -2.92% in last session, and over the past year, it grew by 86.17%%.
Data on historical trading for Akebia Therapeutics Inc. (NASDAQ:AKBA) indicates that the trading volumes over the past 3 months, they’ve averaged 4.81 million. According to company’s latest data on outstanding shares, there are 194.58 million shares outstanding.
Nearly 10.84% of Akebia Therapeutics Inc.’s shares belong to company insiders and institutional investors own 18.84% of the company’s shares. The stock has risen by 7.26% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AKBA stock heading into the next quarter.
